OCM
SWTX

Ovata Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Ovata Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-95,664
Closed -$4.22M – 56
2025
Q1 		$4.22M Buy
+95,664
New +$4.4M 1.6% 16

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Ovata Capital Management's SWTX Position: Q2 2025 in Review

Ovata Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 95,664 shares — an estimated $4.22M sold.

Ovata Capital Management first reported a position in SWTX in Q1 2025 and held it in 1 quarter. The position peaked at $4.22M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Ovata Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ovata Capital Management sold 95,664 SpringWorks Therapeutics shares in Q2 2025, an estimated $4.22M.
  • Ovata Capital Management first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 1 quarter.
  • Ovata Capital Management's SpringWorks Therapeutics position peaked at $4.22M in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Ovata Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.